 Joseph Sottnik
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 8 | 2015 | 272 | 2.390 |
Why?
| | Osteosarcoma | 7 | 2014 | 100 | 2.170 |
Why?
| | Carcinoma, Lobular | 3 | 2026 | 59 | 1.760 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2026 | 430 | 1.300 |
Why?
| | Cell Cycle Proteins | 2 | 2026 | 633 | 1.200 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 261 | 1.190 |
Why?
| | Breast Neoplasms | 4 | 2026 | 2420 | 1.070 |
Why?
| | Dog Diseases | 3 | 2010 | 141 | 0.840 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2026 | 137 | 0.820 |
Why?
| | DNA Repair | 1 | 2026 | 256 | 0.790 |
Why?
| | Trans-Activators | 1 | 2026 | 398 | 0.790 |
Why?
| | Prostatic Neoplasms | 4 | 2015 | 986 | 0.770 |
Why?
| | Hyaluronan Receptors | 2 | 2021 | 105 | 0.760 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2026 | 1457 | 0.740 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 100 | 0.720 |
Why?
| | Nuclear Proteins | 1 | 2026 | 745 | 0.650 |
Why?
| | Receptors, Androgen | 1 | 2021 | 149 | 0.600 |
Why?
| | Glycogen Debranching Enzyme System | 1 | 2019 | 2 | 0.590 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 406 | 0.540 |
Why?
| | Cell Proliferation | 6 | 2021 | 2529 | 0.520 |
Why?
| | Cell Line, Tumor | 9 | 2026 | 3565 | 0.480 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1339 | 0.440 |
Why?
| | Pressure | 1 | 2015 | 228 | 0.410 |
Why?
| | Neoplasm Metastasis | 4 | 2018 | 695 | 0.400 |
Why?
| | Extracellular Matrix Proteins | 1 | 2014 | 156 | 0.380 |
Why?
| | Osteoclasts | 1 | 2013 | 57 | 0.380 |
Why?
| | Dogs | 5 | 2014 | 518 | 0.380 |
Why?
| | Integrin alpha2beta1 | 1 | 2012 | 3 | 0.380 |
Why?
| | Mice | 13 | 2026 | 18491 | 0.380 |
Why?
| | Phosphoproteins | 1 | 2014 | 337 | 0.360 |
Why?
| | Wnt4 Protein | 2 | 2024 | 20 | 0.350 |
Why?
| | Neovascularization, Pathologic | 2 | 2010 | 287 | 0.350 |
Why?
| | Antimetabolites | 1 | 2011 | 21 | 0.350 |
Why?
| | Deoxyglucose | 1 | 2011 | 51 | 0.340 |
Why?
| | Interleukin-11 Receptor alpha Subunit | 1 | 2010 | 4 | 0.320 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2026 | 939 | 0.320 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 748 | 0.320 |
Why?
| | Lymphocyte Count | 1 | 2010 | 165 | 0.310 |
Why?
| | Biopsy, Fine-Needle | 1 | 2010 | 79 | 0.310 |
Why?
| | Oxidative Phosphorylation | 1 | 2011 | 212 | 0.310 |
Why?
| | Luciferases | 1 | 2010 | 155 | 0.300 |
Why?
| | Glycolysis | 1 | 2011 | 341 | 0.300 |
Why?
| | Tumor Burden | 1 | 2010 | 327 | 0.290 |
Why?
| | Animals | 14 | 2026 | 38410 | 0.280 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 347 | 0.260 |
Why?
| | Osteomyelitis | 1 | 2009 | 146 | 0.250 |
Why?
| | Mice, Nude | 3 | 2021 | 680 | 0.240 |
Why?
| | Flow Cytometry | 1 | 2010 | 1172 | 0.240 |
Why?
| | Pyrazoles | 1 | 2010 | 518 | 0.240 |
Why?
| | Mammary Glands, Human | 1 | 2026 | 71 | 0.240 |
Why?
| | Mice, Inbred C3H | 3 | 2011 | 254 | 0.230 |
Why?
| | Phthalazines | 1 | 2026 | 63 | 0.220 |
Why?
| | Blotting, Western | 4 | 2013 | 1186 | 0.220 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 891 | 0.220 |
Why?
| | Cadherins | 1 | 2026 | 204 | 0.220 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 395 | 0.220 |
Why?
| | Osteocytes | 2 | 2015 | 24 | 0.210 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 212 | 0.210 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.210 |
Why?
| | Parathyroid Hormone-Related Protein | 2 | 2013 | 25 | 0.200 |
Why?
| | Antigens, CD | 1 | 2026 | 562 | 0.190 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1253 | 0.190 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 192 | 0.180 |
Why?
| | Disease Models, Animal | 2 | 2010 | 4604 | 0.180 |
Why?
| | Ligands | 1 | 2024 | 675 | 0.170 |
Why?
| | Osteoblasts | 2 | 2014 | 146 | 0.170 |
Why?
| | MCF-7 Cells | 1 | 2021 | 133 | 0.160 |
Why?
| | Angiogenesis Inhibitors | 2 | 2013 | 239 | 0.160 |
Why?
| | Tamoxifen | 1 | 2021 | 193 | 0.160 |
Why?
| | Breast | 1 | 2021 | 157 | 0.160 |
Why?
| | Epithelial Cells | 1 | 2026 | 1141 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 2 | 2011 | 365 | 0.150 |
Why?
| | Wnt3A Protein | 1 | 2019 | 11 | 0.150 |
Why?
| | Neoplasm Transplantation | 2 | 2010 | 246 | 0.150 |
Why?
| | Acyltransferases | 1 | 2019 | 78 | 0.150 |
Why?
| | Butylhydroxybutylnitrosamine | 1 | 2019 | 5 | 0.150 |
Why?
| | In Vitro Techniques | 2 | 2011 | 1049 | 0.150 |
Why?
| | Humans | 15 | 2026 | 147293 | 0.150 |
Why?
| | Signal Transduction | 2 | 2024 | 5272 | 0.140 |
Why?
| | Female | 9 | 2026 | 80076 | 0.140 |
Why?
| | Genetic Engineering | 1 | 2019 | 89 | 0.140 |
Why?
| | Chloroquine | 1 | 2018 | 54 | 0.140 |
Why?
| | Macrolides | 1 | 2018 | 68 | 0.140 |
Why?
| | Lysosomes | 1 | 2018 | 133 | 0.130 |
Why?
| | Neoplasms | 2 | 2010 | 2946 | 0.130 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1730 | 0.130 |
Why?
| | Monocytes | 2 | 2010 | 539 | 0.130 |
Why?
| | rho Guanine Nucleotide Dissociation Inhibitor beta | 1 | 2016 | 4 | 0.120 |
Why?
| | Osteopontin | 1 | 2016 | 37 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 443 | 0.120 |
Why?
| | Chemokine CCL5 | 1 | 2015 | 40 | 0.110 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 95 | 0.110 |
Why?
| | Transcriptome | 1 | 2021 | 1059 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2679 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1794 | 0.100 |
Why?
| | Urologic Neoplasms | 1 | 2013 | 31 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 87 | 0.100 |
Why?
| | Male | 8 | 2021 | 73950 | 0.100 |
Why?
| | Osteoprotegerin | 1 | 2013 | 24 | 0.100 |
Why?
| | RANK Ligand | 1 | 2013 | 29 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2013 | 71 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1171 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 889 | 0.090 |
Why?
| | Bone Resorption | 1 | 2013 | 81 | 0.090 |
Why?
| | Disease-Free Survival | 2 | 2013 | 779 | 0.090 |
Why?
| | Pyrroles | 1 | 2013 | 221 | 0.090 |
Why?
| | Apoptosis | 1 | 2021 | 2454 | 0.090 |
Why?
| | Prognosis | 1 | 2021 | 4383 | 0.090 |
Why?
| | DNA Primers | 1 | 2012 | 505 | 0.090 |
Why?
| | Cathepsin L | 1 | 2011 | 9 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2019 | 3153 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 376 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2231 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 980 | 0.080 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2010 | 78 | 0.080 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 170 | 0.080 |
Why?
| | Cell Adhesion | 1 | 2011 | 451 | 0.080 |
Why?
| | Stem Cells | 1 | 2014 | 630 | 0.080 |
Why?
| | Indoles | 1 | 2013 | 510 | 0.070 |
Why?
| | Carboplatin | 1 | 2010 | 168 | 0.070 |
Why?
| | Microvessels | 1 | 2010 | 98 | 0.070 |
Why?
| | Base Sequence | 1 | 2012 | 2175 | 0.070 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2010 | 269 | 0.070 |
Why?
| | Mice, Inbred Strains | 1 | 2009 | 397 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 784 | 0.070 |
Why?
| | Tibia | 1 | 2010 | 177 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2011 | 721 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 300 | 0.070 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 6041 | 0.070 |
Why?
| | Transfection | 1 | 2010 | 930 | 0.070 |
Why?
| | Doxorubicin | 1 | 2010 | 411 | 0.060 |
Why?
| | Bone and Bones | 1 | 2010 | 322 | 0.060 |
Why?
| | Cell Movement | 1 | 2011 | 966 | 0.060 |
Why?
| | Survival Analysis | 1 | 2010 | 1386 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2014 | 2054 | 0.060 |
Why?
| | Survival Rate | 1 | 2011 | 2110 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 481 | 0.060 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2026 | 222 | 0.050 |
Why?
| | Cell Lineage | 1 | 2026 | 381 | 0.050 |
Why?
| | Cell Line | 1 | 2010 | 2832 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2026 | 340 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 643 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2010 | 886 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 840 | 0.050 |
Why?
| | Chronic Disease | 1 | 2009 | 1844 | 0.050 |
Why?
| | Phenotype | 1 | 2011 | 3216 | 0.050 |
Why?
| | Macrophages | 1 | 2009 | 1529 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 112 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2019 | 67 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 7173 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 247 | 0.040 |
Why?
| | Inhibitor of Differentiation Proteins | 1 | 2018 | 2 | 0.040 |
Why?
| | Protein Transport | 1 | 2019 | 442 | 0.030 |
Why?
| | RNA Interference | 1 | 2019 | 477 | 0.030 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 232 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 459 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 445 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2013 | 18 | 0.030 |
Why?
| | Sample Size | 1 | 2013 | 124 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2013 | 54 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2013 | 139 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 337 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 334 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 789 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 975 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 254 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 552 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 2080 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2890 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 11947 | 0.010 |
Why?
| | Aged | 1 | 2013 | 26514 | 0.010 |
Why?
| | Middle Aged | 1 | 2013 | 36821 | 0.010 |
Why?
| | Adult | 1 | 2013 | 41405 | 0.000 |
Why?
|
|
Sottnik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|